IFNA17 and renal cell carcinoma: These pathological situations may bereversed by inhibiting PAF-CPT, as it was reported in two studies where thereduction of PAF-CPT activity in human renal cell carcinoma (RCC) in patientswho had received IFNa, as well as in brain striatum of rats who had receivedCDP-choline, resulted in reduced levels of PAF with beneficial effects(inhibition of tumor progression and various disorders of the central nervoussystem) in both cases [12, 13].